Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience

Philip, Chepsy C; Selvarajan, Sushil; Nayak, Lingaraj; Jain, Hasmukh; Kulkarni, Uday; Samuel, Prasanna; Agrawal, Narendra; Kayal, Smita; Mishra, Kundan; Pavitra, D S; Das, Smita; PK, Jayachandran; Bala, Stalin; Raghavan, Vineetha; Paul, Mobin; Singh, Jagdeep; Mehta, Prashant; Vasudevan, Sreeraj; Majumdar, Swaratika; Nayak, Akshatha; Prakash, Om; Marimuthu, S.; Rajendra, Akhil; Thorat, Jayashree; Bagal, Bhausaheb; Abraham, Aby; Bhurani, Dinesh; Ganesan, Prasanth; Sengar, Manju

doi:10.1182/blood-2022-165770

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The severe acute respiratory syndrome-coronavirus 2 (SARS-Cov-2) pandemic, which began in 2019 (COVID-19), paralyzed healthcare systems on global scale [ 28 ]. Patients with AML were at risk for SARS-CoV-2 infection not only due to malignancy-related immunodeficiency but also related to the treatment they received [ 29 ]. Hospitalization and repeated outpatient visits have been shown to increase the risk of infection [ 30 ].…”

Section: Treatment Related Barriersmentioning

confidence: 99%

“…Hospitalization and repeated outpatient visits have been shown to increase the risk of infection [ 30 ]. Travel restrictions during the pandemic period and patients’ avoidance of infection risk may have reduced outpatient attendance [ 29 ]. During the pandemic, bed occupancy rates of hospitals increased, inpatient leukemia treatment and allogeneic transplantation processes became more difficult, blood donations decreased, and blood bank reserves decreased, all of which led to problems with supportive care [ 28 ].…”

Section: Treatment Related Barriersmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial

Genç¹,

Saraç

Arslan

et al. 2023

Oncol Ther

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) can affect individuals of all ages, but is more common in older adults. It has been estimated that AML accounted for 1% of all newly diagnosed cancers in the USA in 2022. The diagnostic process varies depending on the presenting symptoms and the healthcare facility that patients attend at diagnosis. The treatment process is long and prone to complications, requiring experienced medical professionals and appropriate infrastructure. Treatment of the disease did not change greatly over the years until 2017 when targeted therapies were licensed. The treatment of AML is associated with significant direct economic costs. A number of obstacles originating both from individual patients and the healthcare system may be encountered during the diagnosis and treatment of the disease, which may negatively impact the optimal management of the disease process. In this article, we focus primarily on the social, operational, and financial obstacles including the corona virus disease 2019 (COVID-19) pandemic experienced during the diagnosis and treatment of AML.

show abstract

Section: Treatment Related Barriersmentioning

confidence: 99%